Welcome to the official website of the Korean Joint Registry for Alzheimer’s Treatment and Diagnostics (JOYALZ).

JOYALZ is a multi-center, real-world registry project launched by the Korean Dementia Association (KDA) to advance clinical care and basic research in Alzheimer’s Disease (AD).

With the rapid advancements in the development of treatments and diagnostic technologies for AD, JOYALZ was established to systematically collect and analyze real-world data on new drugs and diagnostic methods for AD that have been approved since 2021. Through this registry,

we aim to gather valuable insights into prescription patterns, the long-term safety and efficacy of treatments, and patient outcomes in real-world clinical settings. Additionally, we strive to accumulate data on the utilization and effectiveness of novel diagnostic methods. By sharing this crucial data, we hope to foster collaboration among clinicians, researchers, and other experts, ultimately contributing to the advancement of AD treatment and research.

At JOYALZ, our vision is to enhance the understanding of AD, advance prevention and treatment strategies, and ultimately help create a world free from the suffering caused by AD.

To achieve this, we plan to collaborate with the Alzheimer’s Association’s Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) and other leading institutions worldwide that share our vision.

Through this website, we aim to provide a wealth of professional and valuable resources, including information about JOYALZ registry-related educational programs, academic publications, and ongoing research activities. We hope this platform will serve as a valuable resource for researchers, healthcare professionals, and anyone interested in Alzheimer’s Disease.

Your participation and feedback greatly motivate our efforts, and we are always deeply grateful for your contributions. Thank you for visiting our website, and please feel free to reach out to us with any questions or comments.

Thank you.